Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14489820 | 0.69 | EGLN3 (0.50) | EGLN3FDPSHDAC1HDAC6 | |
| SCHEMBL941137 | 0.69 | EGLN3 (0.50) | EGLN3FDPSHDAC1HDAC6 | |
| SCHEMBL503194 | 0.69 | EGLN3 (0.50) | EGLN3FDPSHDAC1HDAC6 | |
| SCHEMBL16343554 | 0.68 | MEN1 (0.42) | EGLN3 | |
| SCHEMBL460703 | 0.68 | ALDH1A1 (0.34) | CYP1A2 | |
| SCHEMBL16343100 | 0.68 | MEN1 (0.42) | EGLN3 | |
| SCHEMBL16323957 | 0.67 | POLB (0.41) | EGLN3FDPSHDAC1HDAC6 | |
| SCHEMBL22265176 | 0.67 | EGLN3 (0.44) | EGLN3CYP1A2NLRP3HDAC1HDAC6 | |
| SCHEMBL22265177 | 0.67 | EGLN3 (0.44) | EGLN3CYP1A2NLRP3HDAC1HDAC6 | |
| SCHEMBL27535957 | 0.67 | EGLN3 (0.55) | EGLN3FDPSHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2993167-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | Ajinomoto Co., Inc. (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-20160046592-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | AJINOMOTO CO., INC. (JP) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046592-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | PPARG, GPR119, PPARA | EGLN3 1293/4885FDPS 2039/4885CYP1A2 638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.